Researchers at the University of Tsukuba have investigated the changes in the primary evaluation items in phase II clinical ...

Ulcerative colitis (UC) is one of the most severe chronic diseases, causing relentless gastrointestinal pain and ...

Peeples Cancer Institute at Hamilton Medical Center has expanded access to the latest in cancer research for patients in ...

Leiden, the Netherlands Saturday, March 22, 2025, 12:00 Hrs [IST] ...

NIH has launched a human trial for LASSARAB, a dual-purpose vaccine targeting Lassa fever and rabies. Early animal studies ...

First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone and with other drug combinations.

The combined companies will operate under the name Kalaris Therapeutics, Inc. and expects to report initial data from part 1 ...

Annovis made significant progress by advancing the buntanetap program, successfully completing two clinical trials-Phase 2/3 ...

The company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.

LUND, SWEDEN / ACCESS Newswire / March 21, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today announces that Dr. Sumeet Ambarkhane MD, Chief Medical Officer, will be leaving Alligator by end o ...

Equillium (NASDAQ:EQ – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on ...

The NIH announced the beginning of a phase 1 first-in-human trial of a vaccine for Lassa fever, a potentially fatal viral hemorrhagic disease for which there is no approved vaccine or treatment.